Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
Status:
Suspended
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
A double-blind, placebo-controlled study that aims to investigate the effect of 2-week and
12-week administration of USP methylene blue (MB) on cerebral blood flow, functional
connectivity, memory and attention cognitive abilities using fMRI and behavioral measures in
healthy aging, mild cognitive impairment (MCI) and mild Alzheimer's disease (AD) subjects.
Phase:
Phase 2
Details
Lead Sponsor:
Peter Fox The University of Texas Health Science Center at San Antonio
Collaborators:
Texas Alzheimer's Research and Care Consortium (TARCC) Texas Alzheimer’s Research and Care Consortium (TARCC)